900 Third Avenue, 19th Floor
About Yamo Pharmaceuticals
Yamo Pharmaceuticals is a clinical stage pharmaceutical company founded in 2015 to develop L1-79, a novel therapy with the potential to improve the core symptoms of Autism spectrum disorder. L1-79 is a novel, well-tolerated mechanism that targets the central nervous system and metabolic symptoms of autism. More information may be found at www.yamopharma.com.
4 articles with Yamo Pharmaceuticals
Yamo Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study of L1-79 in Autism Spectrum Disorder
Yamo Pharmaceuticals today announced that the first patient has been treated in a Phase 2 study of L1-79 in adolescents and young adults with ASD at six U.S. research centers of excellence.
Yamo Pharmaceuticals Receives Investment from Autism Impact Fund to Support Phase 2 Study of L1-79 in Autism Spectrum Disorder
Yamo Pharmaceuticals, LLC announced that The Autism Impact Fund has made a capital investment in Yamo to support a Phase 2 study of L1-79 in adolescents and adults with ASD.
Yamo Pharmaceuticals Presents Results from Phase 2 Study of L1-79 in Adolescents and Young Adult Males with Autism Spectrum Disorder at INSAR 2019
Yamo Pharmaceuticals, LLC announced the presentation of results from a Phase 2 study with L1-79 in the treatment of ASD.
Yamo Pharmaceuticals, LLC, announced today that the US Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug L1-79.